NO924060L - Peg-imidater og proteinderivater derav - Google Patents

Peg-imidater og proteinderivater derav

Info

Publication number
NO924060L
NO924060L NO92924060A NO924060A NO924060L NO 924060 L NO924060 L NO 924060L NO 92924060 A NO92924060 A NO 92924060A NO 924060 A NO924060 A NO 924060A NO 924060 L NO924060 L NO 924060L
Authority
NO
Norway
Prior art keywords
water
peg
imidates
soluble
soluble polymer
Prior art date
Application number
NO92924060A
Other languages
English (en)
Norwegian (no)
Other versions
NO924060D0 (no
Inventor
David E Wright
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of NO924060D0 publication Critical patent/NO924060D0/no
Publication of NO924060L publication Critical patent/NO924060L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91Polymers modified by chemical after-treatment
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33303Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
    • C08G65/33306Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group acyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polyamides (AREA)
  • Polyethers (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO92924060A 1991-10-21 1992-10-20 Peg-imidater og proteinderivater derav NO924060L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77979891A 1991-10-21 1991-10-21

Publications (2)

Publication Number Publication Date
NO924060D0 NO924060D0 (no) 1992-10-20
NO924060L true NO924060L (no) 1993-04-22

Family

ID=25117605

Family Applications (2)

Application Number Title Priority Date Filing Date
NO92924060A NO924060L (no) 1991-10-21 1992-10-20 Peg-imidater og proteinderivater derav
NO971085A NO971085D0 (no) 1991-10-21 1997-03-10 Vannopplöselig polymer og peptid modifisert med denne

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO971085A NO971085D0 (no) 1991-10-21 1997-03-10 Vannopplöselig polymer og peptid modifisert med denne

Country Status (9)

Country Link
EP (1) EP0539167A3 (ko)
JP (2) JP3342060B2 (ko)
KR (1) KR100233777B1 (ko)
AU (2) AU658231B2 (ko)
CA (1) CA2080891A1 (ko)
FI (1) FI924747A (ko)
NO (2) NO924060L (ko)
NZ (1) NZ244778A (ko)
ZA (1) ZA928099B (ko)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
GB9317618D0 (en) * 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
SK166695A3 (en) * 1994-03-31 1997-02-05 Amgen Inc Mgdf polypeptide for stimulating growth and megakaryocyte differentiation
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996041813A2 (en) * 1994-11-09 1996-12-27 Offord Robin E Functionalized polymers for site-specific attachment
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
AU5773798A (en) * 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
EP1062230B1 (en) 1998-03-05 2004-10-13 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
TWI257394B (en) 1998-10-23 2006-07-01 Kirin Amgen Inc Thrombopoietic compounds
DE60022336T2 (de) * 1999-04-02 2006-06-22 Ajinomoto Co., Inc. Vefahren zur herstellung von peptiduntereinheiten aus polymer-proteinen
EP1525889A1 (en) 2000-05-15 2005-04-27 F. Hoffmann-La Roche Ag Liquid pharmaceutical composition containing an erythropoietin derivative
EP1527094B1 (en) * 2002-08-09 2008-07-16 MERCK PATENT GmbH T-cell epitopes in erythropoietin
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
RS20050502A (en) 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of interferon- beta with enhanced biological potency
US7074755B2 (en) 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
JP2007537986A (ja) 2003-05-30 2007-12-27 セントカー・インコーポレーテツド トランスグルタミナーゼを用いる新規なエリトロポエチン複合体の形成
DE10358213A1 (de) * 2003-12-12 2005-07-28 Clariant Gmbh Polyethylenglykol und dessen Herstellung
ES2460671T3 (es) 2003-12-19 2014-05-14 F. Hoffmann-La Roche Ag Uso de eritropoyetina en el tratamiento de alteraciones de la distribución del hierro en enfermedades intestinales inflamatorias crónicas
WO2006010057A2 (en) 2004-07-08 2006-01-26 Amgen Inc. Therapeutic peptides
CA2611836A1 (en) * 2005-06-13 2006-12-21 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
JP2008308690A (ja) * 2007-06-13 2008-12-25 Bio-Cancer Treatment Internatl Ltd ポリ(エチレングリコール)機能性誘導体およびその製造方法
US8507659B2 (en) 2007-11-28 2013-08-13 Fujifilm Corporation Method for chemically modifying biopolymer and polypeptide
CN101455844B (zh) * 2007-12-10 2011-09-14 江苏豪森药业股份有限公司 聚乙二醇化促红细胞生成素偶联物和其制备方法与用途
PT2621519T (pt) 2010-09-28 2017-10-04 Aegerion Pharmaceuticals Inc Polipéptido de fusão de leptina-abd com duração de ação melhorada
CN116515120B (zh) * 2023-06-07 2024-01-26 中石油(上海)新材料研究院有限公司 一种含三嗪环的聚酰胺弹性体及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
WO1990006128A1 (en) * 1988-12-05 1990-06-14 Biogen, Inc. Methods and compositions for inhibiting platelet aggregation
JPH06506217A (ja) * 1991-03-18 1994-07-14 エンゾン,インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体

Also Published As

Publication number Publication date
NO971085D0 (no) 1997-03-10
AU668841B2 (en) 1996-05-16
EP0539167A3 (en) 1993-08-04
KR930008017A (ko) 1993-05-20
NO971085L (no) 1993-04-22
JP2003012697A (ja) 2003-01-15
AU1168495A (en) 1995-06-01
AU658231B2 (en) 1995-04-06
NZ244778A (en) 1994-03-25
CA2080891A1 (en) 1993-04-22
FI924747A (fi) 1993-04-22
JPH05214092A (ja) 1993-08-24
ZA928099B (en) 1994-04-20
EP0539167A2 (en) 1993-04-28
NO924060D0 (no) 1992-10-20
FI924747A0 (fi) 1992-10-20
KR100233777B1 (ko) 1999-12-01
AU2718392A (en) 1993-04-22
JP3342060B2 (ja) 2002-11-05

Similar Documents

Publication Publication Date Title
NO924060L (no) Peg-imidater og proteinderivater derav
CN109187835B (zh) 一种含蛋白质类中药的专属性肽段的鉴别方法
NO20070619L (no) Forbindelser og fremgangsmater for immunterapi og diagnose av tuberkulose.
RU2604521C2 (ru) Сополимер-1, способы его получения и аналитические методы
JP2009542864A (ja) コポリマー1の調製のための改良法
Wilms et al. Exact determination of UV-induced crosslinks in 16S ribosomal RNA in 30S ribosomal subunits.
NO991694L (no) Forbindelser og metoder for immunoterapi og diagnose av tuberkulose
DK1218751T3 (da) Cöliakidiagnose under anvendelse af et gliadinepitop
BR9402666A (pt) Sistema e método de execução de um algoritmo sequencial de compactação de dados e aperlho de compactação de dados
EA200000860A1 (ru) Выделенный полинуклеотид (варианты), полинуклеотид (варианты), вектор (варианты), клетка-хозяин (варианты), выделенный полипептид (варианты), способ его получения (варианты), вакцинная композиция (варианты), способ терапевтического или профилактического лечения стрептококковой бактериальной инфекции у животного (варианты), применение (варианты)
US3925267A (en) Polymeric carrier for a controlled synthesis of peptides
CA2072620A1 (en) Urinary tumor associated antigen, antigenic subunits uses and methods of detection
WO1998022499A3 (en) Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof
Giralt et al. Diketopiperazine formation in acetamido-and nitrobenzamido-bridgedpolymeric supports.
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
FI950378A (fi) Immuunitesti kollageenin tai kollageenifragmenttien havaitsemiseksi
ATE109512T1 (de) Expression und diagnose mit gag-kodierten peptiden, die mit antikörpern gegen lav immunologisch reaktiv sind.
Benicourt et al. In vitro synthesis of turnip yellow mosaic virus coat protein in a wheat germ cell-free system
PL316935A1 (en) Heparin bonding protein for treating septicaemia and method of obtaining such protein
EP0704528A3 (en) Rabbit hemorrhagic disease virus (RHDV) recombinant capsids and proteins, diagnostic kits and vaccines containing them
Oikawa et al. A light scattering study on gelatin gels chemically crosslinked in solution
Smith et al. A rapid assay for the initiation of protein synthesis in extracts of animal cells
CA2112701A1 (en) Proteins s polypeptides and uses thereof
Hudecz et al. Influence of side-chain-terminating moieties on the conformation of branched polypeptides and their conjugates with 4-ethoxymethylene-2-phenyl-5 (4H)-oxazolone
RU2161489C2 (ru) Усовершенствованный сополимер-1 в сополимерных композициях